Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors

被引:4
|
作者
Yi, Min [1 ]
Lin, Heather [2 ]
Bedrosian, Isabelle [1 ]
Shen, Yu [2 ]
Hunt, Kelly K. [1 ]
Chavez-MacGregor, Mariana [3 ,4 ]
King, Tari A. [5 ,6 ]
Mittendorf, Elizabeth A. [5 ,6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Houston, TX 77030 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, Boston, MA 02215 USA
关键词
SURVIVAL; VALIDATION; BURDEN;
D O I
10.1245/s10434-019-07983-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The American Joint Committee on Cancer (AJCC) breast cancer pathological prognostic stage, which incorporates biologic factors, was developed using data from patients undergoing upfront surgery, and its application in patients receiving neoadjuvant chemotherapy (NAC) is unknown. We previously developed the Neo-Bioscore, incorporating clinical and pathological TNM categories with biologic factors, to improve the prognostic stratification of NAC patients. Objective. This study was undertaken to evaluate the use of available staging models incorporating biologic factors in NAC patients. Methods. Patients treated with NAC between 2005 and 2012 at MD Anderson (n = 2363) were staged using the Neo-Bioscore and the AJCC 8th edition: (1) clinical anatomic stage; (2) pathological anatomic stage; (3) clinical prognostic stage; and (4) pathological prognostic stage. Five-year disease-specific survival (DSS) and overall survival (OS) rates, along with Harrell's concordance index (C-index), were estimated. A National Cancer Database (NCDB) cohort (n = 12,887) treated with NAC between 2010 and 2013 was used for validation. Results. In the MD Anderson cohort, staging systems incorporating biologic factors better predicted DSS (bias-corrected C-index: pathological prognostic stage = 0.8026; Neo-Bioscore = 0.7483) and OS (bias-corrected C-index: pathological prognostic stage = 0.7780; Neo-Bioscore = 0.7260) than those using anatomic factors only. Similar results were seen in the NCDB cohort. In pairwise comparisons, the pathological prognostic stage was significantly better (p < 0.0001) than other staging systems in all comparisons except for OS in the NCDB cohort, where it was not significantly different than the Neo-Bioscore (p = 0.2). Conclusion. Biologic factors are important for determining prognosis in patients receiving NAC. These data indicate that the 8th edition AJCC pathological prognostic stage is applicable in these patients.
引用
收藏
页码:359 / 366
页数:8
相关论文
共 50 条
  • [1] The Utility of an Extensive Postchemotherapy Staging Evaluation in Patients Receiving Neoadjuvant Chemotherapy for Bladder Cancer
    Reese, Adam C.
    Ball, Mark W.
    Gandhi, Nilay
    Gorin, Michael A.
    Netto, George J.
    Bivalacqua, Trinity J.
    Schoenberg, Mark P.
    UROLOGY, 2014, 84 (02) : 358 - 363
  • [2] Staging for Breast Cancer With Internal Mammary Lymph Nodes Metastasis: Utility of Incorporating Biologic Factors
    Lian, Chen-Lu
    Zhang, Hai-Yan
    Wang, Jun
    Lei, Jian
    Hua, Li
    Chen, Yong-Xiong
    Wu, San-Gang
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [3] Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging
    Kantor, Olga
    Niu, Jiangong
    Zhao, Hui
    Giordano, Sharon H.
    Hunt, Kelly K.
    King, Tari A.
    Mittendorf, Elizabeth A.
    Chavez-MacGregor, Mariana
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (07) : 2229 - 2237
  • [4] Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy
    Kantor, Olga
    Laws, Alison
    Pastorello, Ricardo G.
    King, Claire
    Wong, Stephanie
    Dey, Tanujit
    Schnitt, Stuart
    King, Tari A.
    Mittendorf, Elizabeth A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (12) : 7347 - 7355
  • [5] Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System Review of the Supporting Evidence
    Weiss, Anna
    King, Tari A.
    Hunt, Kelly K.
    Mittendorf, Elizabeth A.
    SURGICAL CLINICS OF NORTH AMERICA, 2018, 98 (04) : 687 - +
  • [6] Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer
    Read, Rebecca L.
    Flitcroft, Kathy
    Snook, Kylie L.
    Boyle, Frances M.
    Spillane, Andrew J.
    ANZ JOURNAL OF SURGERY, 2015, 85 (05) : 315 - 320
  • [7] Incorporation of biologic factors for the staging of de novo stage IV breast cancer
    He, Zhen-Yu
    Lian, Chen-Lu
    Wang, Jun
    Lei, Jian
    Hua, Li
    Zhou, Juan
    Wu, San-Gang
    NPJ BREAST CANCER, 2020, 6 (01)
  • [8] Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
    Gwark, Sungchan
    Ahn, Hee-Sung
    Yeom, Jeonghun
    Yu, Jiyoung
    Oh, Yumi
    Jeong, Jae Ho
    Ahn, Jin-Hee
    Jung, Kyung Hae
    Kim, Sung-Bae
    Lee, Hee Jin
    Gong, Gyungyub
    Lee, Sae Byul
    Chung, Il Yong
    Kim, Hee Jeong
    Ko, Beom Seok
    Lee, Jong Won
    Son, Byung Ho
    Ahn, Sei Hyun
    Kim, Kyunggon
    Kim, Jisun
    CANCERS, 2021, 13 (24)
  • [9] Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy
    Harter, Dawn
    O'Connor, Siobhan M.
    Hertel, Johann D.
    Calhoun, Benjamin C.
    HISTOPATHOLOGY, 2023, 83 (03) : 453 - 464
  • [10] Pathologic response as predictor of recurrence, metastasis, and survival in breast cancer patients receiving neoadjuvant chemotherapy and total mastectomy
    Zhang, Jiaqiang
    Su, Mingyang
    Chang, Enqiang
    Lu, Chang-Yun
    Chen, Ho-Min
    Wu, Szu-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (10): : 3415 - 3427